Diabetes blindness risk reduced with ARBs

Mon, 15 Sep 2008
According to a major new diabetes trial, angiotensin receptor blockers could lower the risk of retinopathy amongst patients with diabetes . The DIRECT study indicated that prescribing candesartan to people with diabetes could lower the incidence and progression of retinopathy.

Diabetic retinopathy is one of the complications of diabetes, a set of healthcare problems that develop over time when blood glucose levels fluctuate. Treating type 1 diabetics with candesartan at an early stage could help to avoid retinopathy. The medication was also found to be effective in people with type 2 diabetes .

Professor of clinical epidemiology at Imperial College London, Nish Chaturverdi, was reported as commenting: "This trial does provide GPs - and prescribing advisors - with evidence that candesartan, in addition to its other benefits, can reduce the incidence of diabetic retinopathy and slow its progression and development. This offsets the future costs of diabetic complications."
Leave a Comment
Login via Facebook, Yahoo! and Hotmail
Have your full say in the Diabetes Forum
Your comments may be moderated. Please report any spam, illegal, offensive or libellous posts.